NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: These results demonstrated that NF-κB activation via inflammatory signals was crucial for the survival of CML LSCs in the presence of imatinib, and NF-κB activation via either BCR-ABL1 or inflammatory signals was enough to maintain CML LSCs.